nach oben

Clinical Rheumatology

Erschienen in:

02.11.2020 | Original Article

Factors associated with event-free survival in Chinese patients with Takayasu’s arteritis

verfasst von: Yu Wei, Cheng Zhao, Jun Liang, Ziyi Jin, Bingzhu Hua, Hong Wang, Huayong Zhang, Xuebing Feng

Erschienen in: Clinical Rheumatology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To investigate long-term outcomes of Takayasu’s arteritis (TA) and explore the predictive factors associated with poor prognosis.

Methods

We performed a retrospective study on consecutive TA patients admitted to the Nanjing Drum Tower Hospital during the period from July 2010 to March 2019. Potential factors contributing to adverse outcomes, including death, vascular complications, and vascular stenosis aggravation were assessed by Cox regression analysis.

Results

Seventy-one individuals were enrolled, in which 90.1% were female. The mean onset age was 29.44 ± 11.75 years, and mean follow-up time was 3.42 ± 2.38 years. Adverse outcomes were observed in twenty-five (35.2%) patients, and the 1-, 5-, and 8-year event-free survival was 94.2%, 61.8%, and 29.8% respectively. Univariable Cox regression revealed that pulmonary hypertension (PH) (HR 4.13), high total cholesterol levels (HR 4.49), high LDL cholesterol levels (HR 5.14), and low-dose cyclophosphamide (CTX) treatment (HR 0.53) were associated with adverse outcomes. Among them, only CTX treatment remained significant in multivariable Cox regression analysis (HR 0.62). Interestingly, compared to those ineffective to CTX, the responders had higher immunoglobulin A levels (p < 0.05) but lower CRP levels (p < 0.05).

Conclusions

Even with vigorous therapy, a large proportion of TA patients may present adverse outcomes along with the development of disease. Low-dose CTX treatment is helpful for a better prognosis.

Key Points

• The prognosis of Takayasu’s arteritis is still poor.

• Application of low-dose cyclophosphamide in high-risk patients helps to improve the outcome.

• Abnormal lipid profiles may contribute to the development of this disease, which also deserves attention.

Fan L, Zhang H, Cai J, Yang L, Liu B, Wei D, Yu J, Fan J, Song L, Ma W, Zhou X, Wu H, Lou Y (2019) Clinical course and prognostic factors of childhood Takayasu’s arteritis: over 15-year comprehensive analysis of 101 patients. Arthritis Res Ther 21(1):31. https://doi.org/10.1186/s13075-018-1790-xCrossRefPubMedPubMedCentral

Dourmishev AL, Serafimova DK, Vassileva SG, Dourmishev LA, Schwartz RA (2005) Segmental ulcerative vasculitis: a cutaneous manifestation of Takayasu’s arteritis. Int Wound J 2(4):340–345. https://doi.org/10.1111/j.1742-4801.2005.00103.xCrossRefPubMedPubMedCentral

Baymakova M, Demirev A, Kostadinova I, Andonova R, Popov GT, Plochev K (2018) Giant-cell arteritis without cranial manifestations presenting as fever of unknown origin: a diagnostic value of 18F-FDG PET/CT. Clin Ter 169(6):e274–e276. https://doi.org/10.7417/CT.2018.2092CrossRefPubMed

Comarmond C, Biard L, Lambert M, Mekinian A, Ferfar Y, Kahn JE, Benhamou Y, Chiche L, Koskas F, Cluzel P, Hachulla E, Messas E, Resche-Rigon M, Cacoub P, Mirault T, Saadoun D, French Takayasu N (2017) Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation 136(12):1114–1122. https://doi.org/10.1161/CIRCULATIONAHA.116.027094CrossRefPubMed

Fragoulis GE, Evangelatos G, Iliopoulos A (2019) Takayasu arteritis: “bitten apple” in the aorta, odd finding in a plain X-ray. Clin Rheumatol 38(11):3307–3308. https://doi.org/10.1007/s10067-019-04711-1CrossRefPubMed

Barra L, Yang G, Pagnoux C, Canadian Vasculitis N (2018) Non-glucocorticoid drugs for the treatment of Takayasu’s arteritis: a systematic review and meta-analysis. Autoimmun Rev 17(7):683–693. https://doi.org/10.1016/j.autrev.2018.01.019CrossRefPubMed

Kim ESH, Beckman J (2018) Takayasu arteritis: challenges in diagnosis and management. Heart 104(7):558–565. https://doi.org/10.1136/heartjnl-2016-310848CrossRefPubMed

Basu N, Karabayas M, Pusey C (2018) Prognosis and future developments in vasculitis. Best Pract Res Clin Rheumatol 32(1):148–165. https://doi.org/10.1016/j.berh.2018.08.011CrossRefPubMed

Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, Masi AT, McShane DJ, Mills JA, Stevens MB, Wallace SL, Zvaifler NJ (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33(8):1129–1134. https://doi.org/10.1002/art.1780330811CrossRefPubMed

10.

Skeik N, Ostertag-Hill CA, Garberich RF, Alden PB, Alexander JQ, Cragg AH, Manunga JM, Stephenson EJ, Titus JM, Sullivan TM (2017) Diagnosis, management, and outcome of aortitis at a single center. Vasc Endovasc Surg 51(7):470–479. https://doi.org/10.1177/1538574417704296CrossRef

11.

Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M (2016) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol (Engl Ed) 69(2):177. https://doi.org/10.1016/j.rec.2016.01.002CrossRef

12.

Hata A, Noda M, Moriwaki R, Numano F (1996) Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 54(Suppl):S155–S163. https://doi.org/10.1016/s0167-5273(96)02813-6CrossRefPubMed

13.

Agueda AF, Monti S, Luqmani RA, Buttgereit F, Cid M, Dasgupta B, Dejaco C, Mahr A, Ponte C, Salvarani C, Schmidt W, Hellmich B (2019) Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open 5(2):e001020. https://doi.org/10.1136/rmdopen-2019-001020CrossRefPubMedPubMedCentral

14.

Keser G, Aksu K, Direskeneli H (2018) Takayasu arteritis: an update. Turk J Med Sci 48(4):681–697. https://doi.org/10.3906/sag-1804-136CrossRefPubMed

15.

Misra DP, Sharma A, Kadhiravan T, Negi VS (2017) A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis. Autoimmun Rev 16(2):179–191. https://doi.org/10.1016/j.autrev.2016.12.009CrossRefPubMed

16.

Sun Y, Ma L, Ma L, Kong X, Chen H, Lv P, Lin J, Liu H, Yan Y, Ji Z, Yang C, Dai S, Wan W, Zou Y, Jin X, Jiang L (2017) Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu’s arteritis. Rheumatol Int 37(12):2019–2026. https://doi.org/10.1007/s00296-017-3847-6CrossRefPubMed

17.

Henes JC, Mueller M, Pfannenberg C, Kanz L, Kotter I (2011) Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 29(1 Suppl 64):S43–S48PubMed

18.

Langford CA (2011) Cyclophosphamide as induction therapy for Wegener’s granulomatosis and microscopic polyangiitis. Clin Exp Immunol 164(Suppl 1):31–34. https://doi.org/10.1111/j.1365-2249.2011.04364.xCrossRefPubMedPubMedCentral

19.

Thomas K, Vassilopoulos D (2017) Infections and vasculitis. Curr Opin Rheumatol 29(1):17–23. https://doi.org/10.1097/BOR.0000000000000348CrossRefPubMed

20.

Sari A, Sener YZ, Firat E, Armagan B, Erden A, Oksul M, Hekimsoy V, Asil S, Kilic L, Kiraz S, Kaya EB, Tokgozoglu L, Akdogan A (2018) Pulmonary hypertension in Takayasu arteritis. Int J Rheum Dis 21(8):1634–1639. https://doi.org/10.1111/1756-185X.13354CrossRefPubMed

21.

Direskeneli H (2019) Pulmonary hypertension in Takayasu’s arteritis: should be monitored closely. Int J Cardiol 276:238–239. https://doi.org/10.1016/j.ijcard.2018.10.074CrossRefPubMed

22.

Toledano K, Guralnik L, Lorber A, Ofer A, Yigla M, Rozin A, Markovits D, Braun-Moscovici Y, Balbir-Gurman A (2011) Pulmonary arteries involvement in Takayasu’s arteritis: two cases and literature review. Semin Arthritis Rheum 41(3):461–470. https://doi.org/10.1016/j.semarthrit.2011.06.001CrossRefPubMed

23.

Wang X, Chen B, Lv N, Liu Q, Dang A (2015) Association of abnormal lipid spectrum with the disease activity of Takayasu arteritis. Clin Rheumatol 34(7):1243–1248. https://doi.org/10.1007/s10067-014-2819-4CrossRefPubMed

24.

Tang W, Yao L, Roetker NS, Alonso A, Lutsey PL, Steenson CC, Lederle FA, Hunter DW, Bengtson LG, Guan W, Missov E, Folsom AR (2016) Lifetime risk and risk factors for abdominal aortic aneurysm in a 24-year prospective study: the ARIC study (Atherosclerosis Risk in Communities). Arterioscler Thromb Vasc Biol 36(12):2468–2477. https://doi.org/10.1161/ATVBAHA.116.308147CrossRefPubMedPubMedCentral

25.

Pan L, Du J, Chen D, Zhao Y, Guo X, Qi G, Wang T, Du J (2019) Takayasu arteritis with dyslipidemia increases risk of aneurysm. Sci Rep 9(1):14083. https://doi.org/10.1038/s41598-019-50527-zCrossRefPubMedPubMedCentral

26.

Kwon OC, Oh JS, Park MC, Hong S, Lee CK, Yoo B, Kim YG (2019) Statins reduce relapse rate in Takayasu arteritis. Int J Cardiol 287:111–115. https://doi.org/10.1016/j.ijcard.2019.02.046CrossRefPubMed

Titel: Factors associated with event-free survival in Chinese patients with Takayasu’s arteritis
verfasst von: Yu Wei
Cheng Zhao
Jun Liang
Ziyi Jin
Bingzhu Hua
Hong Wang
Huayong Zhang
Xuebing Feng
Publikationsdatum: 02.11.2020
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 5/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05481-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Serum uric acid as a sensitive concordant marker with lupus nephritis and new onset of renal damage: a prospective cohort study

External validation of Gout-calculator performance on a cohort of acute arthritis (SYNOLACTATE) sparing distal joints such as hallux and midfoot. A cross-sectional study of 170 patients

Risk of serious infection, malignancy, or death in Japanese rheumatoid arthritis patients treated with a combination of abatacept and tacrolimus: a retrospective cohort study

Clinical characteristics and prognosis of concomitant systemic lupus erythematosus and primary biliary cholangitis

Rebuttal letter on “Comment on Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis—time to reconsider treatment guidelines? A case series and review of literature”